Fruehauf JP, et al. - In this study performed on chemotherapy-naive patients with metastatic melanoma, researchers assessed the safety and clinical activity of pazopanib in combination with metronomic paclitaxel. Six-month progression-free survival (PFS) rate was mainly assessed among patients who received pazopanib at a starting dose of 800 mg daily in combination with metronomic dosing of paclitaxel 80 mg/m² weekly thrice every 4 weeks. They found significant activity shown by the combination of pazopanib and metronomic paclitaxel in patients with metastatic melanoma. This combination therapy was well-tolerated by patients.